Hemophilia Treatment Market 2020 by Opportunity, Demand, Recent trends, Major Driving Factors and Business Growth Strategies and Forecast 2026 -…

Market Research Report on Hemophilia Treatment Market Size Analysis and Outlook to 2026- Potential Opportunities, Companies, and Forecasts across diverse technology across End User Industries and Countries

A market research firm Facts & Factors (FnF) published a market research report on Hemophilia Treatment Market By Product (Desmopressin, Antifibrinolytic Agents, Plasma Derived Coagulation Factor Concentrates, and Recombinant Coagulation Factor Concentrates), By Disease (Hemophilia A, Hemophilia B, Hemophilia C, and Others), By Therapy (Replacement Therapy, ITI Therapy, Gene Therapy, and Antibody Therapy), By Treatment Type (On-demand and Prophylaxis), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), And By Region: Global Industry Outlook, Market Size, Business Intelligence, Consumer Preferences, Statistical Surveys, Comprehensive Analysis, Historical Developments, Current Trends, and Forecasts, 20202026that includes 190+ pages research report with TOC in its research offerings.

The 2020 series of Hemophilia Treatment market size, share, outlook, and growth prospects is a comprehensive analysis of Hemophilia Treatment market conditions. Major trends shaping the near and long term future of the industry, opportunities, drivers, and restraints of Hemophilia Treatment market, detailed porters five forces analysis and competitive insights are included in the research report.

The latest market report by Facts and Factors Market Research on the Hemophilia Treatment market evaluates the opportunities and current market scenario, providing insights and updates about the corresponding segments involved in the Hemophilia Treatment market for the forecast period of 2020-2026. The report provides a detailed assessment of key market dynamics and comprehensive information about the structure of the Hemophilia Treatment market. This market study contains exclusive insights into how the Hemophilia Treatment market is anticipated to grow during the forecast period of 2020-2026.

Request an Exclusive Free Sample Report of Hemophilia Treatment Market: http://www.fnfresearch.com/sample/global-hemophilia-treatment-market-by-product-desmopressin-antifibrinolytic-790

(The sample of this report is readily available on request).

Benefits of Requesting a FREE Sample Report Before Purchase:

Global Hemophilia Treatment Market Analysis by Company

Top leading companies in the Hemophilia Treatment market are analyzed in the report along with their business overview, operations, geographical locations, financial analysis, SWOT profile, and Carbon Black products & services.

Some of Following Top Market Players Profile Included in This Report:

BioMarin Pharmaceutical Inc., Novo Nordisk, CSL Behring, Shire Plc., Pfizer Inc., Biogen, Bayer Healthcare, Chugai Pharmaceutical Co., and Baxalta

Key indicators of market growth, which include compound annual growth rate (CAGR) and Year-on-Year (Y-o-Y) growth of the mark are explained in FnFs study in a comprehensive manner in Hemophilia Treatment market. Also, it includes definition, drivers, and opportunity analysis, which helps in the deep understanding of the market segments by researchers, suppliers, manufactures, and distributors. This information can help readers understand the quantitative growth prospects of the Hemophilia Treatment market during the forecast period.

The report presents in-depth insights into each of the leading Carbon Black applications along with annual forecasts to 2026. Various applications that are studied in the Hemophilia Treatment market report.

The multi-client study on Hemophilia Treatment markets provides in-depth research and analysis into Hemophilia Treatment industry trends, market developments, and technological insights. The report provides data and analysis of Hemophilia Treatment penetration across application segments across countries and regions.

Enquire more about this report before purchase @ http://www.fnfresearch.com/inquiry/global-hemophilia-treatment-market-by-product-desmopressin-antifibrinolytic-790

(You may enquire a report quote OR available discount offers to our sales team before purchase.)

COVID-19- Current Scenario & Potential Impact

Various communities and companies are doing their best to function and perform, and eventually cope with the challenges raised by COVID-19 pandemic. The COVID-19 pandemic had a negative impact on the market size for the year 2020, with small and medium scale companies struggling to sustain their businesses in the near term future. Industry leaders are now focusing to create new business practices to deal with crisis situations like COVID-19 pandemic.

The report presents a strategic analysis of the Hemophilia Treatment market through key drivers, challenges, opportunities, and growth contributors. Further, the market attractiveness index is provided based on five forces analysis.

The Hemophilia Treatment market delivers value to customers through reliable market size for 2019 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Hemophilia Treatment market size to 2026.

Request Customized Copy of Report @ http://www.fnfresearch.com/customization/global-hemophilia-treatment-market-by-product-desmopressin-antifibrinolytic-790

(We customize your report according to your research need. Ask our sales team for report customization.)

Scope of the Hemophilia Treatment Market report includes-

1. The base year for the market analysis is 2019 and forecasts are provided from 2020 to 2026

2. Annual Forecasts of Hemophilia Treatment markets, 2020 to 2026

3. Hemophilia Treatment Market Size as a whole, 2020- 2026

4. Market Size of Hemophilia Treatment across Types, 2020- 2026

5. Hemophilia Treatment other segments, 2020- 2026

6. Applications and End-User Verticals, 2020- 2026

7. Hemophilia Treatment Market across Countries and Regions, 2020- 2026

8. Regions covered- Asia Pacific, Europe, Middle East, and Africa, North America, Latin America

Reasons to Buy Hemophilia Treatment Market Report:

The nature of Hemophilia Treatment business opportunities has grown in complexity with the industry evolving at a greater pace, making it increasingly difficult going without adequate information on markets and companies.

The Hemophilia Treatment market report assists users to:

For media or urgentEnquiriesMail Us At sales@fnfresearch.com

About Us:

Facts & Factors is a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background. Our wide-ranging database offers statistics and detailed analysis of different industries worldwide that help the clients in achieving sustainable progress. The well-organized reports help clients in developing strategies and making informed business decisions.

Contact Us:

Facts & Factors

A 2108, Sargam, Nanded City, Sinhagad Road, Pune 411041, India USA: +1-347-989-3985

E-Mail: sales@fnfresearch.com

Web: http://www.fnfresearch.com

Continue reading here:
Hemophilia Treatment Market 2020 by Opportunity, Demand, Recent trends, Major Driving Factors and Business Growth Strategies and Forecast 2026 -...

2025 Growth: EGFR Mutation Test Market 2020: Growth, Latest Trend Analysis and Forecast 2025 – 3rd Watch News

The study on the EGFR Mutation Test Marketby Brand Essence Market Research is a compilation of systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also offers a precise analysis of the key challenges and growth prospects awaiting key players of the EGFR Mutation Test market, including a concise summary of their corporate strategies and competitive setting.

In 2018, the Global EGFR Mutation Test Market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

Download Premium Sample of the Report: https://industrystatsreport.com/Request/Sample?ResearchPostId=12351&RequestType=Sample

EGFR Mutation TestMarket unveilsasuccinctanalysisofthemarketsize, regionalspectrumandrevenueforecastaboutthe EGFR Mutation Testmarket.Furthermore,the reportpointsoutmajorchallengesandlatestgrowth plansembracedbykeymanufacturersthatconstitute thecompetitivespectrumofthisbusinessdomain.

Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are referred to as EGFR-mutated tumors. EGFR mutation is generally observed in NSCLCs, especially in adenocarcinoma tumors. According to the International Association for the Study of Lung Cancer, American Thoracic Society and European Respiratory Society, there are around 50% of surgically resected lung adenocarcinomas in EGFR mutations. These mutations are related to micro papillary predominant subtype and the bronchioloalveolar carcinoma. EGFR biomarker is used in diagnosis of patients with NSCLC. Targeted therapy involving tyrosine kinase inhibitors such as gefitinib and erotinib is used in the treatment of patients with NSCLC. EGFR biomarker detects the presence of specific alterations in EGFR gene, which may lead to the development of tumor.

Increasing global prevalence of lung cancer is expected to fuel growth of the global EGFR mutation test market over the forecast period. Increasing adoption of biomarker therapy is also expected to boost growth of the market worldwide over the forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for EGFR Mutation Test. This report studies the global market size of EGFR Mutation Test, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).

This study presents the EGFR Mutation Test production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

In global market, the following companies are covered:

Abbott Merck Thermo Fisher Scientific Illumina BioMerieux QIAGEN Agilent Technologies Hologic Novartis Roche Genomic Health

Market Segment by Product Type

DNA Sequencing Kits

Market Segment by Application

Cancer Hospitals Clinical Research Institutes

In this study, the years considered to estimate the market size of EGFR Mutation Test are as follows:

History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025

The analysis provides an exhaustive investigation of the global EGFR Mutation Test market together with the future projections to assess the investment feasibility. Furthermore, the report includes both quantitative and qualitative analyses of the EGFR Mutation Test market throughout the forecast period. The report also comprehends business opportunities and scope for expansion. Besides this, it provides insights into market threats or barriers and the impact of regulatory framework to give an executive-level blueprint the EGFR Mutation Test market. This is done with an aim of helping companies in strategizing their decisions in a better way and finally attains their business goals.

The study objectives are:

To analyze and research the EGFR Mutation Test status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast. To present the key EGFR Mutation Test manufacturers, presenting the sales, revenue, market share, and recent development for key players. To split the breakdown data by regions, type, companies and applications To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends, drivers, influence factors in global and regions To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

Table of Contents

1 Report Overview 1.1 Study Scope 1.2 Key Market Segments 1.3 Players Covered 1.4 Market Analysis by Type 1.4.1 Global EGFR Mutation Test Market Size Growth Rate by Type (2014-2025) 1.4.2 Topical Products 1.4.3 Botulinum 1.4.4 Dermal Fillers 1.4.5 Chemical Peels 1.4.6 Microabrasion Equipment 1.4.7 Laser Surfacing Treatments 1.5 Market by Application 1.5.1 Global EGFR Mutation Test Market Share by Application (2014-2025) 1.5.2 Hospitals 1.5.3 Dermatology Clinics 1.6 Study Objectives 1.7 Years Considered

2 Global Growth Trends 2.1 EGFR Mutation Test Market Size 2.2 EGFR Mutation Test Growth Trends by Regions 2.2.1 EGFR Mutation Test Market Size by Regions (2014-2025) 2.2.2 EGFR Mutation Test Market Share by Regions (2014-2019) 2.3 Industry Trends 2.3.1 Market Top Trends 2.3.2 Market Drivers 2.3.3 Market Opportunities

3 Market Share by Key Players 3.1 EGFR Mutation Test Market Size by Manufacturers 3.1.1 Global EGFR Mutation Test Revenue by Manufacturers (2014-2019) 3.1.2 Global EGFR Mutation Test Revenue Market Share by Manufacturers (2014-2019) 3.1.3 Global EGFR Mutation Test Market Concentration Ratio (CR5 and HHI) 3.2 EGFR Mutation Test Key Players Head office and Area Served 3.3 Key Players EGFR Mutation Test Product/Solution/Service 3.4 Date of Enter into EGFR Mutation Test Market 3.5 Mergers & Acquisitions, Expansion Plans

Read More: https://industrystatsreport.com/Lifesciences-and-Healthcare/EGFR-Mutation-Test-Market-Growth-Rate-Demands-and-Status/Summary

About us: Brandessence Market Research and Consulting Pvt. ltd.

Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.

Contact us at: +44-2038074155 or mail us at [emailprotected]

Link:
2025 Growth: EGFR Mutation Test Market 2020: Growth, Latest Trend Analysis and Forecast 2025 - 3rd Watch News

Hemophilia Treatment Market 2020 By End-User Demand, Emerging Trend, New Innovations, Future Prospect, Detailed Analysis and Forecast 2027 – 3rd Watch…

Hemophilia Treatment Market In-Depth Analysis, Regional Outlook

Hemophilia is a condition where blood does not clot, and this condition is normally inherited. The condition is caused due to defects in a gene of the X chromosome, which is a clotting factor. Generally, the diseases are widely seen in males as the X chromosome is inherited from mother to baby boy. The disease is widely treated with replacement therapy and gene therapy. The other treatment which is used is medication. However, there are ways to reduce the risk of the condition, which include regular exercise and others. The condition can be prevented by taking preventive treatment by injection of clotting factor VIII for hemophilia A, or IX for hemophilia B.

The hemophilia treatment market was valued at US$ 14,454.81 million in 2019 and is expected to grow at a CAGR of 15.9% from 2020 to 2027 to reach US$ 44,089.71 million by 2027.

Request Sample Copy of Hemophilia Treatment Market at:https://www.theinsightpartners.com/sample/TIPRE00008241/

Some of the key players profiled in the study areBayer AG, Sanofi, F. Hoffmann-la Roche Ltd., Kedrion S.P.A., CSL Limited, Biotest AG, Pfizer Inc., Novo Nordisk A/S, Octapharma AG, Baxter International Inc., etc.

Hemophilia Treatment Market Trends, Growth, Future Scope

Based on end user, the hemophilia treatment market is segmented into hospitals & clinics, hemophilia treatment centers, and ambulatory surgical centers. The hospitals and clinics held the largest share of end user segment in the global market. Moreover, the same segment is expected to grow at the fastest rate during the coming years. The hospital is a complex organization or an institute that provides health to people through complicated but specialized scientific equipment. The team of trained staff in the hospital, educated in the problems of modern medical science. They are all coordinated together for the common goal of restoring and maintain good health. Medical research is constantly pushing the boundaries of health care and redefining what is and isnt possible. The hospitals offer advanced treatment options as a resource for patients for chronic and hard-to-heal wounds and surgeries to treat them. Most of the surgeries are being performed in hospitals, owing to continuous patient care and monitoring. Also, increasing government funding in the hospitals and rising hospital research drives the market growth.

The research provides answers to the following key questions:

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Hemophilia Treatment market. The researcher provides an extensive analysis of the Hemophilia Treatment market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Hemophilia Treatment industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Global Hemophilia Treatment Market By Product

Global Hemophilia Treatment Market By Disease

Global Hemophilia Treatment Market By Treatment Type

Global Hemophilia Treatment Market By Therapy

Global Hemophilia Treatment Market By End User

Global Hemophilia Treatment Market By Geography

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @https://www.theinsightpartners.com/buy/TIPRE00008241/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read the rest here:
Hemophilia Treatment Market 2020 By End-User Demand, Emerging Trend, New Innovations, Future Prospect, Detailed Analysis and Forecast 2027 - 3rd Watch...

THAILAND’S EXCEPTIONAL STRENGTHS AS THE WORLD’S MEDICAL HUB – Bangkok Post

Thailands internationally-admired performance in the pandemic of the COVID-19 virus has showcased the exceptional strengths of the countrys health care system and medical industry to further justify its drive towards becoming one of the worlds top medical hubs.

A sophisticated healthcare system, universal healthcare coverage and robust public health consciousness have all contributed to Thailands success in containing the pandemic of COVID-19 virus and reporting one of the worlds lowest mortality rates from the disease.

Johns Hopkins Universitys 2019 Global Health Security Index1 ranked Thailand as the worlds 6th best prepared country for confronting the pandemic, reflecting the countrys public health care systems preparedness for coping with major public health emergencies such as the pandemic of the Covid-19 virus.

YouGov in partnership with the Institute of Global Health Innovation at Imperial College London released results from a survey2 in May which showed that Thais are the most likely to wear facemasks in public and use hand sanitizer as hygienic routines, across six countries in Association of Southeast Asian Nations (ASEAN).

This strong local medical environment, together with growing demand for health care locally and from abroad and the Thai governments commitment to further develop the medical industry have enabled Thailand to be the most lucrative market for medical device manufacturing in Asia.

Placing Thailands health care and wellness service and its comprehensive medical industry among 13 key industries that represent the countrys new engines of growth over the next decade in line with the Thailand 4.0 policy, the Thai government has established a plan to develop the countrys medical sector as the global Medical Hub. This policy is a national strategy aiming of creating sustainable human development through the leverage of Thailands strengths in the manufacturing supply chain, the medical industry and biotechnology to build economic competitiveness over the long-term.

This position is reiterated in the Ministry of Public Health 2016-2025 plan for Thailand to become the worlds foremost destination for medical industry in four key areas of wellness, medical services, academic activities and medical products.

Cost advantage, high-quality medical services, attentive care of medical staff and unique wellness services have spurred demand for Thailands medical and wellness from abroad. The Ministry of Tourism & Sports is promoting Thailands medical and wellness tourism at the global level.

Thailands large healthcare industry is currently supported by 370 private hospitals, 50 of which are accredited by the Joint Commission International (JCI) global standard, while there were also 18 JCI-accredited medical clinics as of September 2019. This number is greater than any other countries in ten- membered ASEAN and fourth highest in the world.

Thailands attractive overall investment climate is underlined by rising competitiveness in many areas. The World Bank ranks Thailand at the 21st place out of 190 economies on the 2020 Ease of Doing Business Index, reflecting the countrys conducive regulatory environment for starting and operation of local firms3.

The World Bank also ranks Thailand at the 32nd out of 160 countries on the Logistics Performance Index in 2018, second only to Singapore in ASEAN4 for the biennial study.

These positive factors and Thailands strategic location as the gateway to growing economies of Cambodia, Lao PDR, Myanmar, and Vietnam enable Thailand to offer an ideal investment destination for a wide range of medical device manufacturers and healthcare service providers.

Growing Prospects for Medical Devices

Thailands economic competitiveness, rising demand from aging population,expanding middle class and more tourists seeking affordable high-quality health care services have supported growing future prospect for medical device industry. On top of that, the pandemic of the COVID-19 virus adds an impetus to the demand for a wide range of medical devices from frontline medical practitioners to general populations and accelerates the medical systems adoption of more advanced medical devices.

Thailand boasts a strong industrial manufacturing supply chain and agricultural businesses to support the pharmaceuticals, medical food production and medical device manufacturing.

As a testament to the growing medical industry and importance of export base, Thailands outbound shipment of medical devices grew to US$ 843 million in 2018 from US$ 554 million in 2011. The value of imports grew to US$ 962 million from US$ 557 million, over the same period.

Electromechanical devices, in vitro diagnostic devices, single-use devices,ophthalmic devices, optical devices, and hospital hardware represented Thailands top medical device imports in 2018.

The reliance on the import of sophisticated medical devices underscores the significant potential for investment opportunities in Thailand. Thailand Board of Investment offers a wide range of incentives for investments that meet the national development objectives. The available tax incentives include the exemption of both corporate income tax and import duty on machinery and raw or essential materials used in manufacturing products for the export.

As for non-tax incentives, the BOI also grants the permission for foreign investors to hold up to 100 % ownership in most targeted businesses. Additionally, the BOI enhances the coverage and benefits of its Smart Visa program to attract the high-skilled experts, investors, and foreign start-ups in targeted high- technology industries under the Thailand 4.0 policy.

The BOI also introduces additional incentives to promote new investment by medical device manufacturers and industrial manufacturers who wish to adjust their production to meet the surge in the use of medical devices to cope with the epidemic of the Covid-19 virus.

Thriving Pharmaceutical Market

Thailands Universal Coverage Scheme, which now covers almost all of the countrys 70 million population, the rise in the medical demand from tourists and robust biotechnology have driven Thailand to be one of the strongest- performing pharmaceutical markets to support the medical care and wellness services in the Asia-Pacific region.

As Thailand becomes more integrated in ASEANs trade cooperation,the countrys market share for the export of pharmaceuticals to the Cambodia,Lao PDR, Myanmar and Vietnam and ASEAN countries continues to grow.

Foreign investment in Thailands pharmaceutical sector is also increasing,as the BOI is offering incentives to compensate overseas investors for increased burdens stemming from the upgrade of production facilities required to meet GMP standards (as per the PIC/S requirements). Such incentives include reducing operators costs and, as such, applicants for investment support who made successful applications in 2017-2018 are eligible for an 8-year corporate tax waiver.

The pharmaceuticals and medical device manufacturing sectors are also among the governments targeted industries. If such businesses are established in the Eastern Economic Corridor (EEC) special economic zone which spans Chachoengsao, Chonburi, and Rayong provinces in the countrys Eastern region, they are also eligible for further investment support in the form of financial assistance with research and additional tax waivers.

Leading in R&D

With robust medical systems and the high caliber of their medical researchers, several Thai agencies have established themselves as leaders in the field of research and development and clinical trials in ASEAN. Leading in the battle against Covid-19, Siam Bioscience Co., Ltd. under the collaboration with Thailands Department of Medical Science has produced the first Thai-made RT-PCR test kits for the COVID-19 virus. The test kits, which meet the World Health Organizations standard, were distributed to the medical laboratories across the country for speedy detection of the virus.

To facilitate more advanced biological products, Thailands government has put in place a complete regulatory framework to support local research and development activities such as derivations of blood, vaccine, proteins and Advanced Therapy Medical Products (ATMP) such as cell therapy products, gene therapy products and stem cell therapy products, including the Cell Therapy Act.

The strong governments support, high-quality medical system and lower cost attracts a large number of biotechnology companies and contract research organizations to Thailand to conduct clinical trials for cures in ongoing high prevalence diseases such as HIV/ AIDS, Hepatitis, heart disease, cancer, dengue, malaria and infectious diseases including various strains of flu.

Read the original:
THAILAND'S EXCEPTIONAL STRENGTHS AS THE WORLD'S MEDICAL HUB - Bangkok Post

Biobanking Market to Reach $49.46 Billion by 2026; Recent Breakthrough Concepts have Indicated Potential in Covid-19 Vaccine, says Fortune Business…

Pune, June 18, 2020 (GLOBE NEWSWIRE) -- The global biobanking market size is projected to reach USD 49.46 billion by the end of 2026. The growing investments in development of efficient biobanks and recent studies associated with the use of biobanks in the treatment of the coronavirus will emerge in favor of market growth. According to a report published by Fortune Business Insights, titled "Biobanking Market Size, Share & Industry Analysis, By Sample Storage (Blood, Cells & Tissue, and Others), By Application (Regenerative Medicines, Life Sciences, and Others), By Settings (Academic Medical Institutes, and Pharmaceutical & Biotechnology Companies), and Regional Forecast, 2019-2026," the market was worth USD 25.09 billion in 2018 and will exhibit a CAGR of 8.9% till 2026.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/biobanking-market-102073

Biobanking Can Play a Huge Role in Fighting the Coronavirus

The constant research and collective studies associated with the coronavirus speaks volumes about the seriousness and severity of the disease. It is observed that biobanking has shown potential in the development of treatment options for Covid-19. This will present several growth opportunities for the companies operating in the market.

Biobanking refers to the process wherein blood samples are collected and studied for research and development purposes. This process helps in understanding the cause and effect of several diseases and can also help produce efficient treatment methods for specific diseases through prolonged research and study. The increasing emphasis on biobanking is consequential to the excellent results and outputs in recent years.

As a result, massive investments are being made in the development of efficient processes, with the aim of studying severe and critical diseases. The study of blood can also aid in the health and nutritional requirement s in the human body. Technological advancements have allowed applications such as tracking and real-time examination; a process that has hugely benefited the global biobanking market in recent years.

An Overview of the Impact of COVID-19 on this Market:

The emergence of COVID-19 has brought the world to a standstill. We understand that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies can help in the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost every sector is anticipated to be impacted by the pandemic.

We are taking continuous efforts to help your business sustain and grow during COVID-19 pandemics. Based on our experience and expertise, we will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

To get the short-term and long-term impact of COVID-19 on this Market.

Please visit: https://www.fortunebusinessinsights.com/biobanking-market-102073

United Kingdom Announces $247 DNA Database

The report encompasses several factors that have contributed to the growth of the overall market in recent years. Accounting to the increasing applications of biobanking in several research and studies, there has been a surge in the overall investments in product R&D. The growing investments in product R&D will have a direct impact on the growth of the market in the coming years. In September 2019, the UK announced that it has invested a huge sum in a new database for the Genome Decoding Research Project.

The UK announced USSD 247 million for the project. Through this activity, it will analyze and sequence the genetic codes of 500,000 volunteers. Large scale healthcare and pharma companies such as GlaxoSmithKline plc and Johnson & Johnson are also involved in the project. The high investments in the development of large scale biobank projects similar to this, will have a direct impact on the growth of the overall market in the coming years.

Quick Buy - Biobanking Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/102073

Europe Currently Dominates the Market; Presence of Well-established Biobanks will Aid Growth

The report analyses the latest market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in Europe currently dominates the market. The presence of numerous large scale biobanks in Nordic countries such as Sweden, Denmark, and Norway will contribute to the growth of the market in this region.

It is recorded that around 40% of the total population in Iceland have contributed DNA samples; a factor that will be influential to the growth of the regional market. As of 2018, the market in Europe was worth USD 8.93 billion and this value is projected to increase at a considerable pace in the coming years. The market in Asia Pacific is projected to register a considerable CAGR driven by the high investment in establishing well-structured biobanks.

List of Leading Companies Profiled in the Biobanking Market Report are:

Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/biobanking-market-102073

Detailed Table of Content:

TOC Continued.!!!

Request for Customization: https://www.fortunebusinessinsights.com/enquiry/customization/biobanking-market-102073

Have a Look at Related Reports:

Regenerative Medicine Market Size, Share and Industry Analysis By Product (Cell Therapy, Gene Therapy, Tissue Engineering, Platelet Rich Plasma), By Application (Orthopaedics, Wound Care, Oncology), By Distribution Channel (Hospitals, Clinics) & Regional Forecast, 2019 - 2026

Hemostats Market Size, Share & Industry Analysis, By Product Type (Active Hemostats, Passive Hemostats, Combination Hemostats, Others), By Application (Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, Others), By End User (Hospitals, Ambulatory Surgical Centers, Tactical Combat Casualty Care Centers, Others) and Regional Forecast, 2018-2025

Non-Hodgkin Lymphoma Treatment Market Size, Share & Industry Analysis, By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Others), By Disease Type (B-cell Lymphoma, and T-cell Lymphoma), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2019-2026

Active Pharmaceutical Ingredient (API) Market Size, Share & Industry Analysis, By Type (Generic API, and Branded API), By Synthesis (Biological API, and Synthetic API), and Regional Forecast, 2019-2026

Blood Screening Market Size, Share & Industry Analysis, By Product Type (Instruments, and Reagents & Kits), By Technology (Molecular Tests, and Serology Tests), By End User (Independent Clinical Laboratories, Hospital-based Laboratories, and Others), and Regional Forecast, 2019-2026

Contract Manufacturing Organization (CMO) Market Size, Share & Industry Analysis, By Type (API Manufacturing, Finished Dosage Form Manufacturing (Solid Dosage Forms, Injectables, and Others), and Packaging), and Regional Forecast, 2019-2026

Electronic Health Records (EHR) Market Size, Share & Industry Analysis, By Product (Web-based, On-premise), By Type (Stand Alone, Integrated) By End User (Physician's Office, Hospitals, Others) and Regional Forecast, 2019-2026

Blood Pressure Monitoring Market Size, Share and Industry Analysis By Product Type (Sphygmomanometers, Digital Blood Pressure Monitors, Ambulatory Blood Pressure Monitors), By End User (Hospitals, Ambulatory Surgery Centers & Clinics, Home Healthcare & Others), and Regional Forecast 2018-2025

About Us:

Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.

Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: sales@fortunebusinessinsights.com Fortune Business Insights LinkedIn | Twitter | Blogs

Press Release: https://www.fortunebusinessinsights.com/press-release/biobanking-market-9759

View post:
Biobanking Market to Reach $49.46 Billion by 2026; Recent Breakthrough Concepts have Indicated Potential in Covid-19 Vaccine, says Fortune Business...

Health News Roundup: Ahead of Trump rally in Oklahoma, coronavirus cases; Amazon forest fires could increase risk of COVID infections and more -…

Following is a summary of current health news briefs.

Ahead of Trump rally in Oklahoma, coronavirus cases surge in several states

Just days before U.S. President Donald Trump's campaign rally in Tulsa, the biggest event in the country since pandemic restrictions were imposed in March, new coronavirus cases are surging in Oklahoma, Arizona and other states. The spike in new cases reported on Wednesday and over the last two weeks points to a troubling trend in the United States, where cases have risen nationally after falling for more than a month.

Amazon forest fires could increase risk of serious coronavirus infections

An intense season of fires in the Amazon rainforest this year could overwhelm health systems and lead to unnecessary deaths, including of coronavirus, as pollution worsens respiratory conditions, public health experts said on Wednesday. Forest fires destroy many thousands of hectares of Amazon rainforest across Latin America each year. As peak burning season approaches, experts say intense fires and the particles they give off could exacerbate coronavirus infections.

EU calls for global alliance to buy COVID-19 vaccines up front

The European Commission called on Wednesday for global leaders to cooperate to buy bulk quantities of potential COVID-19 vaccines, to avoid "harmful competition" in the race for a shot and ensure any future vaccine is available for poor countries. With around a dozen potential vaccines now in human trials, rich countries have been rushing to buy up doses in advance from pharmaceutical companies, to make sure they will have enough supply should any prove successful.

Gilead to enroll pediatric patients for late-stage remdesivir study

Drugmaker Gilead Sciences said on Wednesday it will soon begin enrollment of pediatric patients with moderate-to-severe COVID-19 in a late-stage study testing its experimental drug, remdesivir. The trial will assess the effectiveness and safety of the drug in the patients, which would include newborns to adolescents, across more than 30 sites in the United States and Europe, the company said.

Steroid should be kept for serious coronavirus cases, WHO says

A cheap steroid that can help save the lives of patients with severe COVID-19 should be reserved for serious cases in which it has been shown to provide benefits, the World Health Organization said on Wednesday. WHO chief Tedros Adhanom Ghebreyesus said research was at last providing "green shoots of hope" in treating the virus, which has killed more than 400,000 people worldwide and infected more than 8 million.

'Medicaid best price' changes aimed at value-based gene therapy contracts: U.S. agency

Proposed changes to requirements that state-run Medicaid programs are given the best drug prices would clear the way for commercial health insurers to enter into "value-based" payment schemes, the U.S. Centers for Medicare & Medicaid Services said on Wednesday. Drug manufacturers by law must give Medicaid their "best price," meaning the lowest price they negotiate with any other buyer. But health plans have expressed concerns that the requirement prevents them from linking drug prices to patient outcomes - a practice known as "value-based" pricing.

Requiring masks 'political hazard' as COVID-19 surges in California breadbasket

The first wave of COVID-19 came slowly to San Joaquin County in the heart of California's breadbasket, but the much-feared second surge is roaring through, sickening as many people in the two weeks since Memorial Day as in March and April combined. Hospitalizations have spiked by 40%, and the county is one of ten in the most populous U.S. state put on a watch list of places that might be ordered to lock down their economies again after weeks of careful reopening.

Italian study shows no improvement from Roche's rheumatoid arthritis drug for COVID-19

Roche Holding AG's Actemra did not improve symptoms in patients with early-stage COVID-19 pneumonia, scientists conducting a study of the drug in Italy said on Wednesday, raising questions about the potential of the Swiss drugmakers' rheumatoid arthritis drug to treat the novel coronavirus. The study compared patients who received anti-inflammation drug Actemra to those given standard treatment, and concluded that Actemra did not reduce severe respiratory symptoms, intensive care visits, or death.

Black patients with COVID-19 in Atlanta more likely to be hospitalized: CDC

A study of coronavirus patients in Atlanta has found that black patients are more likely to be hospitalized than white patients, highlighting racial disparities in the U.S. healthcare system, researchers from the Centers for Disease Control and Prevention (CDC) said on Wednesday. About 79% of black patients were hospitalized for COVID-19, the disease caused by the novel coronavirus, against 13% of white patients, according to the study https://www.cdc.gov/mmwr/volumes/69/wr/mm6925e1.htm?s_cid=mm6925e1_w across six metropolitan hospitals and outpatient clinics in Atlanta, Georgia, between March and April 2020.

WHO sees 'green shoots' of hope in COVID-19 pandemic

Signs of hope are starting to show in the fight against the COVID-19 pandemic, the World Health Organization (WHO) said on Wednesday, but it added that countries must continue to work on prevention measures to limit the spread of the new coronavirus. While cases are "still rapidly rising" in many regions of the world, there are "green shoots of hope", the WHO's Director General Tedros Adhanom Ghebreyesus said in an online media briefing.

See more here:
Health News Roundup: Ahead of Trump rally in Oklahoma, coronavirus cases; Amazon forest fires could increase risk of COVID infections and more -...

Sexton Biotechnologies Partners with BioSpherix to Create a Fully-Enclosed, Modular Fill-Finish System with Rapid Deployment for Emerging Cell and…

INDIANAPOLIS, June 11, 2020 /PRNewswire/ --Sexton Biotechnologieshas announced a new collaboration withBioSpherix Medical. As a tool and technologies partners of the Cell and Gene industry, Sexton and BioSpherix both recognize the need for cost-effective and flexible automation solutions during cell and gene therapy process development. While some upstream bioprocesses have been successfully automated, the final steps of downstream bioprocess, namely Fill-Finish, are often done manually with associated risks of contamination and user error.

The inefficiencies and lack of traceable GMP controls make manual Fill-Finish processes unacceptable if companies are to scale up and scale out for late-stage clinical or commercial phases. The new collaboration will combine Sexton's off-the-shelf fill system, the Sexton Biotechnologies AF-500, with BioSpherix' exclusive Cytocentric isolator technology, allowing rapid process development and implementation of GMP Fill-Finish.

The recent global pandemic has resulted in an unprecedented acceleration of therapeutic candidates paired with significant supply chain challenges. Development of clinical and commercial stage manufacturing systems to meet this rapid expansion is likely to lead to significant delays in scale up and completion of clinical studies.

BioSpherix, having already observed that traditional GMP capacity is becoming limited, leads the field in manufacture of modular systems that reduce the time and capital burden of implementation. While constructing and operating a Class A or B environment is time and cost-prohibitive for start-up companies, the BioSpherix solution offers an attractive solution to reduce the need for high classification cleanroom, long lead times, and costs.

"The limitations of many of the available downstream processing methods and systems are inherently obvious for cell and gene therapy developers," said Sean Werner, President of Sexton Biotechnologies. "We've taken the approach with the AF-500 to have systems ready to ship so developers can immediately begin process development of small volume fill and finish with the equipment they plan to use at clinical scale. The collaboration with BioSpherix further enhances our current technology enabling it to operate within a fully closed environment along with the ability to control temperatures to limit risks during cryopreservation."

Sexton and BioSpherix recognized each other's capabilities as complimentary and that together, they could address a gap in process capabilities. Sexton's rapidly deployable Fill and Seal system, AF-500, is capable of filling and sealing up to 500 CellSeal vials in 90 minutes and is available for immediate delivery and can be installed for use within a biosafety cabinet while the BioSpherix modular isolator is under construction. The BioSpherix modular isolator can be configured for any manual or automated, large or small, simple or complex bioprocess, making it the perfect fit with Sexton's AF-500 to bring flexibility, sterility, and automation to our customers.

About Sexton:

Sexton Biotechnologies is a revenue stage, biotechnology company focused on the development and sales of bioproduction tools for cell and gene therapy founded in 2019 as a spin-out of Cook Regentec, a life science incubator/accelerator located in Indianapolis, IN. Sexton develops purpose-built CGT tools and media to enable flexible automation and scaling of cell manufacturing processes to increase the probability of positive clinical outcomes and reduce time-to-market, failure points, and labor costs. Sexton's portfolio includes the CellSeal platform of cryo-storage tools and fill/finish systems and human platelet lysate growth supplements. More information atwww.sextonbiotechnologies.com.

About BioSpherix:

BioSpherix Ltd. is a New York based corporation focused for over 20 years on the design and manufacture of Cytocentric Cell Incubation and Processing Systems, a unique equipment platform that controls critical cell process parameters at physiologic levels better than conventional equipment or any alternative, and enables antibiotic-free aseptic cell processing without chemical microbial biocides. The BioSpherix Medical division is the exclusive supplier of the only Cytocentric isolator called theXvivo System model X2, used by cell and gene therapy developers all over the world to produce the most potent cells. Extreme modularity enables it to close any cell production process, retains unlimited flexibility, and accelerates every phase of development at a fraction of the cost of traditional cleanroom suites. Designed to bring GMP to clinics, but just as capable in industrial pharmaceutical factories, including upstream in biotech. More information atwww.biospherixmedical.com.

See the original post:
Sexton Biotechnologies Partners with BioSpherix to Create a Fully-Enclosed, Modular Fill-Finish System with Rapid Deployment for Emerging Cell and...

Choroideremia Treatment Market 2020 Industry Analysis, Share, Size, Demand, Forecast to grow at a steady CAGR | Copernicus Therapeutics, Inc, Wize…

Data Bridge Market Researchhas added an exhaustive research study of theGlobal Choroideremia Treatment Marketdetailing every single market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Competitive Analysis:

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Originally posted here:
Choroideremia Treatment Market 2020 Industry Analysis, Share, Size, Demand, Forecast to grow at a steady CAGR | Copernicus Therapeutics, Inc, Wize...

Genomics Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 – Cole of Duty

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Genomics market.

Trusted Business Insights presents an updated and Latest Study on Genomics Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Genomics market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Genomics Market Size, Share, Growth, Market Research and Industry Forecast Report, 2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Genomics Market

The global genomics market size was estimated at USD 17.2 billion in 2019 and is anticipated to expand at a CAGR of 7.7% over the forecast period. Noninvasive cancer screening-based research is one of the major factors playing a pivotal role in reshaping the genomics industry. Researchers from diverse areas of expertise are engaged in the development and establishment of clinical uses for gene-based liquid biopsy tests.Liquid biopsy solutions identify cancer-causing DNA mutations thus enabling early detection of cancer. Several companies have begun leveraging on genomics for the development of DNA liquid biopsy tests in order to detect cancer at early stage. Increasing applications of genomics in medicine has gained attention from military organizations, resulting in a significant increase in adoption of genetic testing in their healthcare systems. Military practitioners are implementing Carrier Screening for Genetic Conditions guidelines, which recommends Spinal Muscular Atrophy (SMA) screening in pregnant women.

Implementation of human genomics studies across public health programs such as population screening and consumer wellness programs are expected to create lucrative opportunities for the market. These programs are primarily targeted at optimizing preventive care for common chronic diseases such as cancer and heart disease.Traditional genome editing technologies are time-consuming, inefficient, and labor-intensive and have a limited capacity of maintaining pace with the fast-progressing genome modification era. However, advent of CRISPR/Cas9 nuclease, ZFN, and TALEN is set to address these challenges by facilitating easy and precise genome editing.Clinical healthcare is being considered as a gateway for introducing new sequencing technologies for U.S. residents. This trend is propelled by healthcare giants focusing on providing medical genomics across clinical patient care delivery. Also, newly developed gene editing technologies can control and potentially cure specific diseases via detection of underlying mutations in an individual. Thus, innovations in the medical genomics industry are expected to offer profitable opportunities for the market in the near future.Application andTechnology Insights of Genomics Market

Functional genomics is expected to be the largest revenue generating segment by 2027 owing to the generation of large amount of sequencing data. Introduction of high-throughput technologies employed in gene and protein studies has contributed to the segment growth. Advancements in the genomics industry range from studying individual genes to complete genomes and proteomes within a comparatively shorter time durations, which is another factor driving the segment growth.Investigating communication and response in individual targets within the molecular networks has offered useful insights regarding biological functions at a cellular level. Pathway analysis has emerged as a pivotal aspect to strengthen life sciences research along with a fundamental understanding of molecular and cellular biology targeted toward drug development. Thus, the pathway analysis approach is set to gain significant traction post the emergence of personalized therapies and genomics.Integration of genomics in the field of personalized therapy enables an in-depth analysis of navigating signaling pathways and disease networks. This further aids in addressing challenges associated with the development of therapeutics and genetic assays. Various biological resource types including gene ontology, gene annotation databases, and pathway databases can be effectively employed for pathway-based analysis.Deliverable InsightsThere is an increase in the number of demonstrations pertaining to miniaturized instruments targeted toward genomics applications in recent years. These instruments are designed to offer enhanced specificity, sensitivity, and automated features as compared to conventional instruments.However, the development of microfabrication technology and integrated microfluidic genomics systems is now aimed at the development of point-of-care devices. Increasing use of impedimetric detection is one of the promising techniques for the instruments in the market. Moreover, companies such as Formulatrix, Inc. are introducing innovative instruments that help researchers prepare and process samples before subjecting them to analysis.Increasing adoption of cloud-based solutions for robust and effective management of parallelization along with distribution of input data and user code on a large number of computer nodes is expected to propel the software solutions sector. This is anticipated to further contribute to the segment growth.Cloud computing offers a very prominent advantage of performing tasks in different parallel computing nodes along with the processors, which results in a significant reduction in waiting time. Integration of cloud computing solutions in processing NGS related data is expected to have a significant impact on the genomics market growth.End-use InsightsA steep decline in sequencing costs coupled with technological enhancements in informatics, genetic solutions are now widely used across various sectors ranging from small labs to clinical settings. Key end-use segments consist of pharmaceutical and biotechnology companies, hospitals and clinics, academic and government institutes, clinical and research laboratories, and other end users.Among these, the pharmaceutical and biotechnology companies segment is expected to dominate the global market throughout the forecast period owing to increasing number of genetic research studies. These are chiefly aimed at the development of efficacious drugs with fewer side effects and improving drug discovery process. This is also attributed to expanding penetration of genomics across diseases associated with immune system, central nervous system, and cardiovascular system.

Moreover, biotechnology companies are effectively employing gene-editing tools to address challenges pertaining to personalized treatment of patients through development of genetically engineered and recombinant products. Other end users include agriculture research institutes, direct-to-consumers (DTC), and forensic centers. The others segment is anticipated to witness profitable growth owing to significant demand for DTC among consumers, government, and genomics companies.

Regional Insights of Genomics Market

North America is anticipated to emerge as the dominant region in the market owing to rising patient awareness, substantial investments in research by government organizations, and advanced healthcare infrastructure. Changing regulations for usage and reimbursement are expected to fuel the adoption of genetic tests in this region.Presence of key players such as Bio-Rad Laboratories, Inc.; Cepheid, Inc.; Agilent Technologies; and Danaher Corporation have also contributed to the revenue generated by this region. Whereas, companies such as Illumina, Genomic Health, and Bluebird Bio that are operating at the forefront for revolutionizing the genomics industry, are also headquartered in U.S. These companies serve as pioneers in the fields of genetic sequencing, genetic diagnostics, and gene therapy respectively.Asia Pacific is expected to witness the fastest growth in the coming years owing to increasing adoption and awareness for latest genomics technologies in the emerging countries of this region. These technologies are targeted toward detection, treatment, and prognosis of genetic disorders. China is playing a pivotal role in the regional market growth by initiatives such as introduction of the Precision Medicine Initiative (PMI) for the use of genomics in healthcare in 2017.

Market Share Insights of Genomics Market

Major players include F. Hoffmann-La Roche Ltd..; Agilent Technologies, Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; 23andMe, Inc.; Illumina, Inc.; Myriad Genetics, Inc.; Foundation Medicine, Inc.; Danaher; Pacific Biosciences; Oxford Nanopore Technologies; and BGI.In June 2019, BGI partnered with Eluthia, a Germany-based biotechnology company, for the development and commercialization of reproductive genetic tests across Germany. Such alliances are set to intensify the market competition in the near future.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Genomics Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this report, this market research report has segmented the global genomics market report on the basis of application and technology, deliverables, end use, and region:

Deliverable Outlook (Revenue, USD Million, 2019 2030)

Products

Instruments & Software

Consumables & Reagents

Services

Core Genomics Services

NGS-based Services

Biomarker Translation Services

Computational Services

Others

Application & Technology Outlook (Revenue, USD Million, 2019 2030)

Functional Genomics

Transfection

Real-time PCR

RNA interference

Mutational analysis

SNP analysis

Microarray analysis

Epigenetics

Bisulfite sequencing

Chromatin immunoprecipitation-sequencing (ChIP & ChIP-Seq)

Methylated DNA immunoprecipitation (MeDIP)

High resolution melt (HRM)

Chromatin accessibility assays

Microarray analysis

Pathway Analysis

Bead-based analysis

Microarray analysis

Real-time PCR

Proteomics tools (2-D PAGE; yeast 2-hybrid studies)

Biomarker Discovery

Mass spectrometry

Real-time PCR

Microarray analysis

Statistical analysis

Bioinformatics

DNA sequencing

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Clinical & Research Laboratories

Academic & Government Institutes

Hospitals & Clinics

Pharmaceutical & Biotechnology Companies

Other End Users

Quick Read Table of Contents of this Report @ Genomics Market Size, Share, Growth, Market Research and Industry Forecast Report, 2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See more here:
Genomics Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 - Cole of Duty

Developing a COVID-19 Vaccine Quickly Proving to be a Daunting Task But Progress Still Expected – OrthoSpineNews

PALM BEACH, Florida,June 3, 2020/PRNewswire/ Rapid development of a vaccine to prevent the global health crisis is a global imperative, and defining the stakes and potential hurdles is critical because regulatory and medical decisions are based on benefit/risk calculations. The benefit of developing an effective vaccine is very high, and even greater if it can be deployed in time to prevent repeated or continuous epidemics. A recentarticlein the NEW ENGLAND JOURNAL of Medicine said: The need to rapidly develop a vaccine against SARS-CoV-2 comes at a time of explosion in basic scientific understanding, including in areas such as genomics and structural biology, that is supporting a new era in vaccine development. Over the past decade, the scientific community and the vaccine industry have been asked to respond urgently to epidemics of H1N1 influenza, Ebola, Zika, and now SARS-CoV-2. An H1N1 influenza vaccine was developed relatively rapidly, largely because influenza-vaccine technology was well developed and key regulators had previously decided that vaccines made using egg- and cell-based platforms could be licensed under the rules used for a strain change. Although a monovalent H1N1 vaccine was not available before the pandemic peaked in the Northern Hemisphere, it was available soon afterward as a stand-alone vaccine and was ultimately incorporated into commercially available seasonal influenza vaccines.Active biotech companies with recent developments include:Hoth Therapeutics, Inc.(NASDAQ:HOTH),Gilead Sciences, Inc.(NASDAQ:GILD),Inovio Pharmaceuticals, Inc.(NASDAQ:INO),Sorrento Therapeutics, Inc.(NASDAQ:SRNE),Vaxart, Inc.(NASDAQ:VXRT).

Thearticlecontinued: Multiple platforms are under development. Among those with the greatest potential for speed are DNA- and RNA-based platforms, followed by those for developing recombinant-subunit vaccines. RNA and DNA vaccines can be made quickly because they require no culture or fermentation, instead using synthetic processes. Developers and regulators experience with these platforms for personal oncology vaccines can facilitate rapid testing and release. There are no approved RNA vaccines to date, but RNA vaccines have entered clinical trials, and regulators have experience in reviewing clinical trial applications and with associated manufacturing of the vaccines.

Hoth Therapeutics, Inc.(NASDAQ:HOTH)BREAKING NEWS:Hoth Therapeutics Provides Shareholder Update on Therapeutics Pipeline Management provides pipeline update for assets including its COVID-19 vaccine and peptide therapeutic Hoth Therapeutics today is providing an update on its pipeline of therapeutics including six compounds in various stages of clinical development, targeting atopic dermatitis, lupus as well as a COVID-19 vaccine and peptide therapeutic.

Hoth has assembled a unique and portfolio of therapeutics, that is each addressing significant unmet market needs globally, stated Mr.Robb Knie, CEO of Hoth Therapeutics.We have partnered with some of the most renowned doctors, clinics, and scientific institutions as we strive to bring these innovative therapeutic solutions through the clinic. We have several significant milestones upcoming throughout the rest of 2020 into next year including our human study for BioLexa, targeting the treatment of eczema in adolescents.Management remains committed to developing, and bringing these novel treatments to market and improving the lives of those that require them.

BioLexa Platform (Dermatological) The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis or eczema through a non-corticosteroid approach. InJanuary 2020, Hoth concluded its In-life 28-day animal study. The BioLexa Platform has recorded positive results from its pilot project in 2019 and most recently obtained strong data from initial animal testing. Additionally the Company is preparing to begin its first trial in humans later this year.

VNLG-152 (Dermatological) Earlier this year, Hoth acquired the full licensing rights of VNLG-152 novel retinamides (Retinoic acid metabolism blocking agents, or RAMBAs) for the treatment of dermatological diseases. The Company previously announced that pre-clinical work is underway at Weill Cornell Medicine to examine the efficacy of RAMBAs in blocking acne pathogenic gene expression and carcinogenesis in mice. Currently, Hoth is exploring whether VNLG-152 is capable of blocking this inflammatory response. Immediately after identifying an effective dose of VNLG-152, the researchers will conduct studies on mouse skin to determine if this drug is effective in blocking acne-like inflammation. As the Weill Cornell lab reopens later this month Hoth has intentions to finalize results of its preclinical work.

WEG-232 (Dermatological) Last year Hoth entered into a research agreement with theGeorge Washington University(GW) to explore the potential use of WEG-232 for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients. Erlotinib is a drug that is used to combat various cancers and has been known to cause varying degrees of skin rashes, lesions, hair loss and nail changes to patient.A recent research study suggested the topical application of WEG-232 could be very effective in suppressing erlotinib induced-facial rash/hair loss with approximate 71% reduction. It concluded that WEG-232 may be used as an effective intervention to prevent EGFR-TKI-induced cutaneous toxicity. Hoth looks forward to filing a pre-IND with the FDA this year to receive guidance and begin its human trial.

VaxCelerate (COVID-19) VaxCelerateis self-assembling vaccine (SAV) platform designed to protect patients at risk of Coronavirus (COVID-19) infection. VaxCelerate is believed to offer unique advantages over other compounds in combination therapy. In infectious applications, it allows rapid development against viruses and other pathogens. The vaccine focuses on both DNA and internal / external mutated proteins providing the immune system with more potential targets to attack. VaxCelerate is currently in animal trials and will share those results as the testing completes.

Novel Peptide Therapeutic (COVID-19) The Company recently licensedtechnology and intellectual property exclusively fromVirginia Commonwealth University(VCU) for a novel peptide therapeutic to prevent spike protein binding, a potential leading cause of COVID-19.This treatment could be a breakthrough in slowing the transmission of the virus. Current research is being led by inventor,Michael H. Peters, Ph.D., Professor, Department of Chemical and Life Science Engineering at VCU, College of Engineering.The work is being aided, in part, by powerful supercomputers as part of the COVID-19 High Performance Computing Consortium through a virtual system that scientists can use to interactively share computing resources known as the Extreme Science and Engineering Discovery Environment. Hoth hopes to have an update as to further collaboration with VCU in the month ahead.

AEA loaded into Z-pods(Lupus) Developedin partnership with Zyl Therapeutics, Hoths AEZ-loaded Z-podsare currently being tested for approval in the treatment of Cutaneous Lupus Erythematosus(CLE). Scientists have demonstrated that topical administration with AEA-loaded nanoparticles significantly prevents the development of CLE in an established animal model of lupus.

Exon Skipping Approach (Allergic Disease) During Q4 of 2019, Hoth enteredinto a licensing agreement withNorth Carolina State University(NC State) to studyNC StatesExon Skipping Approach for Treating Allergic Diseases. This Exon Skipping Approach was developed by Dr.Glenn Cruse, Principal Investigator and Assistant Professor in the Department of Molecular Biomedical Sciences at the NCState College of Veterinary Medicine. During Dr. Cruses research, a new approach for the technique of antisense oligonucleotide-mediated exon skipping to specifically target and down-regulate IgE receptor expression in mast cells was identified.Through this collaborative project, NCSU looks to establish the most effective approach for targeting genes that regulate surface expression of FcRI in mast cells that mediate allergic airway inflammation.Read the full Press Release and more for HOTH at:https://www.financialnewsmedia.com/news-hoth

Other industry developments from around the markets include:

Gilead Sciences, Inc.(NASDAQ:GILD)recentlyannouncedtopline results from the Phase 3 SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia. This open-label study evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. The study demonstrated that patients in the 5-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group (OR 1.65 [95% CI 1.09-2.48]; p=0.017). The odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care were also favorable, trending toward but not reaching statistical significance (OR 1.31 [95% CI 0.88-1.95]; p=0.18). No new safety signals were identified with remdesivir across either treatment group. Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming weeks.

Our understanding of the spectrum of SARS-CoV-2 infection severity and presentations of COVID-19 continues to evolve, saidFrancisco Marty, MD, an infectious diseases physician at Brigham and Womens Hospital, and associate professor of medicine atHarvard Medical School. These study results offer additional encouraging data for remdesivir, showing that if we can intervene earlier in the disease process with a 5-day treatment course, we can significantly improve clinical outcomes for these patients.

Inovio Pharmaceuticals, Inc.(NASDAQ:INO)recentlyannouncedthe publication of the preclinical study data for IN0-4800, its COVID-19 DNA vaccine, demonstrating robust neutralizing antibody and T cell immune responses against coronavirus SARS-CoV-2. The study was published in the peer-reviewed journal Nature Communications titled, Immunogenicity of a DNA vaccine candidate for COVID-19 by INOVIO scientists and collaborators from The Wistar Institute, theUniversity ofTexas, Public Health England,Fudan University, and Advaccine.

Dr.Kate Broderick, INOVIOs Senior Vice President of R&D and the Team Lead for COVID-19 vaccine development, said,These positive preclinical results from our COVID-19 DNA vaccine (INO-4800) not only highlight the potency of our DNA medicines platform, but also build on our previously reported positive Phase 1/2a data from our vaccine against the coronavirus that causes MERS, which demonstrated near-100% seroconversion and neutralization from a similarly designed vaccine INO-4700. The potent neutralizing antibody and T cell immune responses generated in multiple animal models are supportive of our currently on-going INO-4800 clinical trials.

Sorrento Therapeutics, Inc.(NASDAQ:SRNE)recentlyannouncedit has received clearance from the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application for STI-6129, a CD38-targeting antibody drug conjugate (ADC). STI-6129 utilizes several technology platforms that are under development by Sorrento Therapeutics, including a CD38 specific antibody identified from its fully human G-MABantibody library, its proprietary drug payload Duostatin 5 and its site-specific C-LOCK conjugation technology.

That the FDA cleared our STI-6129 IND application to proceed to human trials is another important milestone forSorrento, stated Dr.Henry Ji, Chairman and CEO of Sorrento Therapeutics. Together with our CD38 CAR-T program, this has the potential to provide additional therapeutic options for patients in need. We are looking forward to further evaluating the safety and efficacy of STI-6129 in clinical trials.

Vaxart, Inc.(NASDAQ:VXRT)a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, recentlyannouncedthat it has selected its lead COVID-19 vaccine candidate and has contracted with KindredBio to manufacture bulk vaccine under cGMP to complement the manufacturing capacity of partner Emergent BioSolutions.

All our COVID-19 vaccine constructs were highly immunogenic in preclinical testing, and we are taking the candidate forward that is expected to generate the broadest immune response in humans, saidSean Tucker, Ph.D., chief scientific officer of Vaxart. In a phase 2 efficacy study that was recently published in theLancet Infectious Diseases, we have demonstrated that our oral H1 flu tablet vaccine protected against influenza infection after just one dose. Based on these results, we believe our vaccines are ideal to protect against mucosal respiratory viruses such as SARS-CoV-2, the virus that causes COVID-19.

InJanuary 2020, Vaxart initiated a program to develop a COVID-19 vaccine based on its VAASToral vaccines platform. The Company evaluated multiple vaccine candidates in its preclinical models and has chosen the lead candidate for cGMP manufacturing and clinical testing based on the magnitude and the breadth of the immune response. Vaxart has contracted with Emergent BioSolutions (Emergent) and Kindred Biosciences, Inc. (KindredBio) to produce bulk vaccine under cGMP for upcoming clinical trials. The vaccine tablets will be manufactured at Vaxart.

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMs market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensatedforty six hundred dollarsfor coverage of news issued by Hoth Therapeutics, Inc. by a non-affiliated third party.

FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as may, future, plan or planned, will or should, expected, anticipates, draft, eventually or projected. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companys annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information:Media Contactemail:editor@financialnewsmedia.com+1(561)325-8757

SOURCE Financialnewsmedia.com

More here:
Developing a COVID-19 Vaccine Quickly Proving to be a Daunting Task But Progress Still Expected - OrthoSpineNews